We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Microalbuminuria Predicts Renal Disease in Hypertension

By LabMedica International staff writers
Posted on 20 Jul 2010
The level of a protein found in urine samples, when compared to the amount of creatinine excreted, is a powerful predictor of long-term development of chronic renal insufficiency (CRI).

Increased urinary albumin is a risk factor for cardiovascular events and clinical nephropathy in patients with diabetes. More...
The urinary albumin to creatinine ratio (ACR) is used to assess the increased probability of clinical nephropathy.

In a study, conducted by Italian scientists, 917 patients who did not have diabetes but had hypertension were enrolled in the investigation and followed-up for 11.7 years. Their urine was assayed for albumin (microalbuminuria) and creatinine and the ratio calculated. Microalbuminuria occurs when the kidney leaks small amounts of albumin into the urine, in other words, when there is an abnormally high permeability for albumin in the renal glomerulus. Microalbuminuria was defined as ACR ≥ 22 mg/g in men and ACR as ≥ 31 mg/g in women.

The follow-up revealed that baseline microalbuminuria was associated with an increased risk for developing CRI; cardiovascular events, both fatal and nonfatal cardiac and cerebrovascular events; and cardiorenal events. Microalbuminuria remained significantly related to CRI and cardiorenal events even after adjustment for several baseline covariates.

The senior author on the study, Roberto Pontremoli, M.D., Ph.D., from the University of Genoa (Genoa, Italy) said. "Our findings emphasize the usefulness of a more widespread evaluation of microalbuminuria in an effort to guide the management of hypertension.” Microalbuminuria is an independent predictor of renal and cardiovascular complications in patients without diabetes and with primary hypertension.

The scientists conclude that patients with microalbuminuria should be aggressively targeted for renal and cardiovascular risk factor reduction, although further investigation is warranted to determine whether specific treatment would help to improve outcomes, as already reported for patients with diabetes. The study was reported online in April 2010 in the Clinical Journal of the American Society of Nephrology (CJASN).

Related Links:

University of Genoa




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.